Amgen Inc. Cost of Revenue
Amgen Inc. (AMGN) reported Cost of Revenue of $2.81 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- Amgen Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $2.81B, a 6.64% decline year-over-year.
- Amgen Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $2.74B, a 7.55% decline year-over-year.
- Amgen Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $2.98B, a 4.37% decline year-over-year.
- Amgen Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $3.08B, a 6.89% decline year-over-year.
- Amgen Inc. cost of goods and services sold for fiscal 2025 was $12.04B, a 6.39% decline from fiscal 2024.
- Amgen Inc. cost of goods and services sold for fiscal 2024 was $12.86B, a 52.15% increase from fiscal 2023.
- Amgen Inc. cost of goods and services sold for fiscal 2023 was $8.45B, a 31.92% increase from fiscal 2022.
- Amgen Inc. cost of goods and services sold for fiscal 2022 was $6.41B, a 0.74% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.81B 10-Q · filed 2026-08-05 | $5.55B 10-Q · filed 2026-08-05 | $8.53B derived: sum of 3 quarters · filed 2026-08-05 | $11.61B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.74B 10-Q · filed 2026-05-01 | $5.72B derived: sum of 2 quarters · filed 2026-05-01 | $8.80B derived: sum of 3 quarters · filed 2026-05-01 | $11.81B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.98B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $6.06B derived: sum of 2 quarters · filed 2026-02-13 | $9.07B derived: sum of 3 quarters · filed 2026-08-05 | $12.04B 10-K · filed 2026-02-13 |
| 2025-09-30 | $3.08B 10-Q · filed 2025-11-05 | $6.09B derived: sum of 2 quarters · filed 2026-08-05 | $9.06B 10-Q · filed 2025-11-05 | $12.17B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.01B 10-Q · filed 2026-08-05 | $5.98B 10-Q · filed 2026-08-05 | $9.09B derived: sum of 3 quarters · filed 2026-08-05 | $12.40B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.97B 10-Q · filed 2026-05-01 | $6.08B derived: sum of 2 quarters · filed 2026-05-01 | $9.39B derived: sum of 3 quarters · filed 2026-05-01 | $12.63B derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $3.11B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $6.42B derived: sum of 2 quarters · filed 2026-02-13 | $9.66B derived: sum of 3 quarters · filed 2026-02-13 | $12.86B 10-K · filed 2026-02-13 |
| 2024-09-30 | $3.31B 10-Q · filed 2025-11-05 | $6.55B derived: sum of 2 quarters · filed 2025-11-05 | $9.75B 10-Q · filed 2025-11-05 | $12.86B derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $3.24B 10-Q · filed 2025-08-06 | $6.44B 10-Q · filed 2025-08-06 | $9.55B derived: sum of 3 quarters · filed 2026-02-13 | $11.35B derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | $3.20B 10-Q · filed 2025-05-02 | $6.31B derived: sum of 2 quarters · filed 2026-02-13 | $8.12B derived: sum of 3 quarters · filed 2026-02-13 | $9.93B derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $3.11B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $4.92B derived: sum of 2 quarters · filed 2026-02-13 | $6.73B derived: sum of 3 quarters · filed 2026-02-13 | $8.45B 10-K · filed 2026-02-13 |
| 2023-09-30 | $1.81B 10-Q · filed 2024-10-31 | $3.62B derived: sum of 2 quarters · filed 2024-10-31 | $5.34B 10-Q · filed 2024-10-31 | $7.09B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $1.81B 10-Q · filed 2024-08-07 | $3.53B 10-Q · filed 2024-08-07 | $5.28B derived: sum of 3 quarters · filed 2025-02-14 | $6.87B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $1.72B 10-Q · filed 2024-05-03 | $3.47B derived: sum of 2 quarters · filed 2025-02-14 | $5.05B derived: sum of 3 quarters · filed 2025-02-14 | $6.57B derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $1.75B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $3.33B derived: sum of 2 quarters · filed 2025-02-14 | $4.84B derived: sum of 3 quarters · filed 2025-02-14 | $6.41B 10-K · filed 2025-02-14 |
| 2022-09-30 | $1.59B 10-Q · filed 2023-10-31 | $3.10B derived: sum of 2 quarters · filed 2023-10-31 | $4.66B 10-Q · filed 2023-10-31 | $6.38B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-30 | $1.51B 10-Q · filed 2023-08-04 | $3.07B 10-Q · filed 2023-08-04 | $4.79B derived: sum of 3 quarters · filed 2024-02-14 | $6.40B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-31 | $1.56B 10-Q · filed 2023-04-28 | $3.28B derived: sum of 2 quarters · filed 2024-02-14 | $4.89B derived: sum of 3 quarters · filed 2024-02-14 | $6.53B derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-31 | $1.72B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $3.33B derived: sum of 2 quarters · filed 2024-02-14 | $4.96B derived: sum of 3 quarters · filed 2024-02-14 | $6.45B 10-K · filed 2024-02-14 |
| 2021-09-30 | $1.61B 10-Q · filed 2022-11-04 | $3.25B derived: sum of 2 quarters · filed 2022-11-04 | $4.74B 10-Q · filed 2022-11-04 | $6.33B derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-06-30 | $1.64B 10-Q · filed 2022-08-05 | $3.13B 10-Q · filed 2022-08-05 | $4.72B derived: sum of 3 quarters · filed 2023-02-09 | $6.29B derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-03-31 | $1.49B 10-Q · filed 2022-04-28 | $3.09B derived: sum of 2 quarters · filed 2023-02-09 | $4.65B derived: sum of 3 quarters · filed 2023-02-09 | $6.14B derived: sum of 4 quarters · filed 2023-02-09 |
| 2020-12-31 | $1.60B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $3.16B derived: sum of 2 quarters · filed 2023-02-09 | $4.65B derived: sum of 3 quarters · filed 2023-02-09 | $6.16B 10-K · filed 2023-02-09 |
| 2020-09-30 | $1.56B 10-Q · filed 2021-11-03 | $3.05B derived: sum of 2 quarters · filed 2021-11-03 | $4.56B 10-Q · filed 2021-11-03 | $5.82B derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-30 | $1.49B 10-Q · filed 2021-08-04 | $3.00B 10-Q · filed 2021-08-04 | $4.25B derived: sum of 3 quarters · filed 2022-02-16 | $5.29B derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-31 | $1.51B 10-Q · filed 2021-04-28 | $2.77B derived: sum of 2 quarters · filed 2022-02-16 | $3.80B derived: sum of 3 quarters · filed 2022-02-16 | $4.81B derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-31 | $1.25B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $2.29B derived: sum of 2 quarters · filed 2022-02-16 | $3.30B derived: sum of 3 quarters · filed 2022-02-16 | $4.36B 10-K · filed 2022-02-16 |
| 2019-09-30 | $1.04B 10-Q · filed 2020-10-29 | $2.05B derived: sum of 2 quarters · filed 2020-10-29 | $3.10B 10-Q · filed 2020-10-29 | $4.20B derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-06-30 | $1.01B 10-Q · filed 2020-07-29 | $2.07B 10-Q · filed 2020-07-29 | $3.16B derived: sum of 3 quarters · filed 2021-02-09 | $4.20B derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-03-31 | $1.05B 10-Q · filed 2020-05-01 | $2.15B derived: sum of 2 quarters · filed 2021-02-09 | $3.19B derived: sum of 3 quarters · filed 2021-02-09 | $4.21B derived: sum of 4 quarters · filed 2021-02-09 |
| 2018-12-31 | $1.10B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | $2.13B derived: sum of 2 quarters · filed 2021-02-09 | $3.16B derived: sum of 3 quarters · filed 2021-02-09 | $4.10B 10-K · filed 2021-02-09 |
| 2018-09-30 | $1.04B 10-Q · filed 2019-10-30 | $2.06B derived: sum of 2 quarters · filed 2019-10-30 | $3.00B 10-Q · filed 2019-10-30 | $4.06B derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | $1.02B 10-Q · filed 2019-07-31 | $1.97B 10-Q · filed 2019-07-31 | $3.03B derived: sum of 3 quarters · filed 2020-02-12 | $4.02B derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | $944.00M 10-Q · filed 2019-05-01 | $2.00B derived: sum of 2 quarters · filed 2020-02-12 | $2.99B derived: sum of 3 quarters · filed 2020-02-12 | $4.02B derived: sum of 4 quarters · filed 2020-02-12 |
| 2017-12-31 | $1.06B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $2.05B derived: sum of 2 quarters · filed 2020-02-12 | $3.07B derived: sum of 3 quarters · filed 2020-02-12 | $4.07B 10-K · filed 2020-02-12 |
| 2017-09-30 | $990.00M 10-Q · filed 2018-10-31 | $2.01B derived: sum of 2 quarters · filed 2018-10-31 | $3.01B 10-Q · filed 2018-10-31 | |
| 2017-06-30 | $1.02B 10-Q · filed 2018-07-27 | $2.02B 10-Q · filed 2018-07-27 | ||
| 2016-12-31 | $4.16B 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |